Brinzolamide/brimonidine fixed combination for open-angle glaucoma and ocular hypertension treatment: hypotensive efficacy and tolerability
- 5 April 2026
- journal article
- Published by Real Time, Ltd. in Russian Ophthalmological Journal
- Vol. 19 (1)
Abstract
The literature review analyzes the data of 12-year clinical use of a fixed combination of 1% brinzolamide and 0.2 % brimonidine (BBFC) in the treatment of glaucoma and ocular hypertension. This drug is an alternative for patients with systemic contraindications in the form of broncho-obstructive syndrome and cardiovascular pathology. The monotherapy BBFC hypotensive effect is 30 % of the IOP initial level and corresponds to that of brinzolamide/brimonidine non-fixed combination. Switching patients with glaucoma and ocular hypertension from monotherapy with brinzolamide or brimonidine to BBFC is accompanied by an additional hypotensive effect at the of 13% of the initial IOP. BBFC has a good additional hypotensive effect in combination with drugs of other pharmaceutical groups, and also effectively relieves the hypertension after laser capsulotomy, intravitreal anti-VEGF injections and phacoemulsification. The most common BBFC ophthalmological adverse effects are conjunctival hyperemia, conjunctivitis, allergic reactions and eye discomfort with a frequency of about 10–20 %.Keywords
This publication has 54 references indexed in Scilit:
- Intraocular pressure-lowering effects and safety of brimonidine/brinzolamide fixed combination after switching from other medicationsJapanese Journal of Ophthalmology, 2022
- Prophylactic effect of brinzolamide–brimonidine fixed combination on intraocular pressure spikes after intravitreal anti-VEGF injectionsInternational Ophthalmology, 2021
- Brinzolamide/Brimonidine Fixed Combination: Simplifying Glaucoma Treatment RegimensOphthalmology and Therapy, 2018
- Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: A Randomized TrialAmerican Journal of Ophthalmology, 2017
- A Randomized Trial of Fixed-Dose Combination Brinzolamide 1%/Brimonidine 0.2% as Adjunctive Therapy to Travoprost 0.004%American Journal of Ophthalmology, 2016
- Randomized Trial of Brinzolamide/Brimonidine Versus Brinzolamide Plus Brimonidine for Open-Angle Glaucoma or Ocular HypertensionAdvances in Therapy, 2014
- Three-Month Randomized Trial of Fixed-Combination Brinzolamide, 1%, and Brimonidine, 0.2%JAMA Ophthalmology, 2013
- Ocular Hypertension Treatment StudyArchives of Ophthalmology (1950), 2009
- Topical 2.0% Dorzolamide vs Oral Acetazolamide for Prevention of Intraocular Pressure Rise After Neodymium:YAG Laser Posterior CapsulotomyArchives of Ophthalmology (1950), 1997
- Improving the Therapeutic Index of Topically Applied Ocular DrugsArchives of Ophthalmology (1950), 1984